Results 111 to 120 of about 48,812 (228)

Ipilimumab

Drugs of the Future, 2006
null Sorbera, L.A., null Bayes, M.
europepmc   +2 more sources

Comprehensive Genomic Profiling Beyond Driver Testing in Non‐Squamous Non‐Small Cell Lung Cancer With Known Drivers

Cancer Science, EarlyView.
Figure 6 Comprehensive genomic profiling identified additional actionable alterations in a substantial proportion of patients with non‐squamous NSCLC despite previously identified driver alterations, with some findings leading to subsequent matched targeted therapies.
Yoshihiro Masui, Tatsuya Yoshida, Yoh Yamaguchi, Jun Miyakoshi, Ryoko Inaba Higashiyama, Akiko Tateishi, Yuki Shinno, Yuji Matsumoto, Yusuke Okuma, Tomonori Mizutani, Hidehito Horinouchi, Kouya Shiraishi, Takashi Kohno, Takafumi Koyama, Noboru Yamamoto, Yasushi Goto   +15 more
wiley   +1 more source

Incidence, severity and potential pathomechanism of immune‐related pruritus in melanoma patients undergoing immune checkpoint inhibitor therapy

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Pruritus is a frequent cutaneous immune‐related adverse event (irAE) associated with immune checkpoint inhibitors (ICI), impacting patients' quality of life. This study investigates the incidence, severity and management of pruritus in melanoma patients treated with ICI.
Andrea Roggo, Nikolina Ivanovic, Patrick Turko, Lukas Kraehenbuehl, Mitchell Levesque, Reinhard Dummer, Barbara Meier‐Schiesser   +6 more
wiley   +1 more source

Ipilimumab was safe and effective in two patients with metastatic melanoma and end-stage renal disease

, 2015
Ludimila Cavalcante,1 Asim Amin,2 Jose Lutzky1 1Department of Hematology and Oncology, Mount Sinai Medical Center, Miami Beach, FL, USA; 2Levine Cancer Institute, Charlotte, NC, USA Abstract: This is a unique report of two cases of patients with end ...
Lutzky, Jose, Lutzky J, Cavalcante L, Amin A, Cavalcante, Ludimila, Amin, Asim   +5 more
core   +1 more source

Improvement of overall survival in patients with cutaneous melanoma at a tertiary care center in Germany from 2001 to 2020

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Systemic treatment of cutaneous melanoma has changed since 2011, with clinical studies demonstrating improved outcomes. This analysis evaluated whether this improvement is evident in a real‐world cohort, focusing on overall survival (OS) and relapse‐free survival (RFS).
Lena Nanz, Claus Garbe, Markus Reitmajer, Andrea Forschner, Yves Maczey‐Leber, Teresa Amaral, Lukas Flatz, Ulrike Leiter   +7 more
wiley   +1 more source

Ipilimumab in melanoma

, 2016
: Introduction: The treatment of melanoma is evolving rapidly over the past few years. Patients with BRAFv600 mutations can be treated with a combination of a BRAF-inhibitor and an MEK-inhibitor.
Specenier, Pol
core  

Clinical Outcomes of Gradual Corticosteroid Tapering for Immune Checkpoint Inhibitor‐Induced Liver Injury

Hepatology Research, EarlyView.
Patients with severe ICI‐induced liver injury are commonly treated with corticosteroids, but the optimal tapering strategy remains uncertain. In this study, a gradual corticosteroid tapering strategy based partly on Japanese clinical practice for autoimmune hepatitis was associated with a low rate of relapse and enabled many patients to safely resume ...
Naoto Soma, Yoshihito Uchida, Kayoko Sugawara, Masamitsu Nakao, Nobuaki Nakayama, Yukinori Imai, Suguru Mizuno, Satoshi Mochida   +7 more
wiley   +1 more source

Ipilimumab-associated optic neuropathy

, 2012
We report a unique case of ipilimumab-associated optic neuropathy in a patient with metastatic ...
Ryan Walsh; Steven Galetta; Madhura Tamhankar
core  

Five‐year survival impact of adjuvant anti‐PD‐1 therapy in a nationwide cohort of stage III melanoma

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This nationwide real‐world cohort study was unable to demonstrate a population‐level survival benefit of adjuvant anti‐PD‐1 in stage III melanoma. Matched analyses suggested higher OS in treated patients. However, limited statistical power and potential residual confounding preclude firm conclusions.
Marie B. Weitemeyer, Neel M. Helvind, Shawez Khan, Pernille Bidstrup, Karina D. Steffensen, Adam Andrzej Luczak, Lars Bastholt, Henrik Schmidt, Inge Marie Svane, Marco Donia, Lisbet R. Hölmich, Eva Ellebaek   +11 more
wiley   +1 more source

Durability of Response with First-Line Combined Immune Checkpoint Inhibitor Therapy Compared to Checkpoint Inhibitor with VEGFR-TKI in Advanced Clear Cell Renal Cell Carcinoma

Kidney Cancer
Over the past several years, four regimens incorporating immune checkpoint inhibitors have become widely used in the front-line setting to treat metastatic clear cell renal cell carcinoma: nivolumab with ipilimumab, axitinib with pembrolizumab ...
Jacob Zaemes, David F. McDermott, Meredith M. Regan, Michael B. Atkins   +3 more
doaj   +1 more source